Biosceptre announces today that Sir Gregory Winter, founder of Cambridge Antibody Technology, Domantis and a co-founder of Bicycle Therapeutics Limited has joined the Board as a non-executive Director.

CAMBRIDGE, UK, May 31, 2016 -Biosceptre, the therapeutic antibody company targeting the nfP2X7 receptor across a broad range of cancers, announced today that Sir Gregory Winter has taken a board position as non-executive Director. Sir Gregory has been strongly associated with Biosceptre since 2011 as chair of its Scientific Advisory Board.

In this role, he provided invaluable guidance driving a better understanding of Biosceptre’s novel nfP2X7 oncology target and translation of the science to enable development of three promising therapeutic candidates. Based on this significant progress to date, Sir Gregory will now take on a broader role within Biosceptre.

Sir Gregory said: “I have taken an interest in Biosceptre since Domantis was involved in developing a domain antibody against nfP2X7. Not only is nfP2X7 an exciting target for the development of antibodies but also vaccines. I am therefore delighted that the Biosceptre programme is now at the stage that it can enter further clinical trials. I look forward to increasing my involvement in Biosceptre by providing guidance as a member of the Board.”

Gavin Currie, Biosceptre’s CEO, said: “I am delighted that Sir Gregory has agreed to join the board of Biosceptre at this exciting time for the company. We have characterised nfP2X7 and its relationship with cancer, leading to the development of a broad therapeutic portfolio. With a successful clinical trial completed, demonstrating safety and a strong indication of efficacy, we have a further three clinical trials planned for 2016. The contribution that Sir Gregory has made as Chair of our Scientific Advisory Board has been invaluable to our progress and his new role as Board Director will help drive our advance into phase I and II trials this year.”

About Sir Gregory Winter:

Sir Gregory Winter is Master of Trinity College Cambridge, and until recently was a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB), serving as both a Head of Division, and as Deputy (and Acting) Director.

Sir Gregory developed technology for making humanised antibodies and human antibodies in bacteria. Many of the therapeutic antibodies on the market now were developed using methods devised by Sir Gregory. As a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), of Domantis (acquired by GSK) and currently of Bicycle Therapeutics Limited, he has unique biotechnology industry experience.

Sir Gregory was elected a Fellow of the Royal Society (FRS) in 1990 and awarded the Royal Medal by the society in 2011 “for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur”. Sir Gregory has also won several international awards including the King Faisal International Prize for Medicine, the Cancer Research Institute William B. Coley Award and the Canada Gairdner International Award. Sir Gregory was appointed Knight Bachelor in 2004.

About Biosceptre:

Biosceptre is a Cambridge, UK headquartered biotechnology company focused on developing next generation cancer treatments targeting nfP2X7 including topical products, systemic antibody-based therapeutics and vaccines, to treat a range of cancer types. With one successful phase I trial completed, Biosceptre will undertake three additional clinical trials in 2016, to progress the following candidates to market:

•      BIL03s, a systemic human domain antibody for treatment of solid tumors (phase 1)

•      BIL06v, a therapeutic vaccine for treatment of solid tumors (phase 1)

•      BIL010t, a topical antibody treatment for Basal Cell Carcinoma (phase 2)

These trials will further advance the use of nfP2X7 as a new and important target for the successful treatment of a range of human cancers.

Biosceptre will give a presentation on the science of nfP2X7 in Chicago on the 3rd of June 2016 at the Sachs’ Associates 2nd Annual Immuno-Oncology: BD&L and Investment Forum.  For more information please visit

Daniel Barton
+61 412 548 824
+1 650 249 4977